Go Pro

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$584.78 -3.31 (-0.56%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$591.80 +7.02 (+1.20%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Advanced

Key Stats

Today's Range
$578.50
$604.14
50-Day Range
$526.44
$588.09
52-Week Range
$518.55
$769.98
Volume
937,070 shs
Average Volume
656,638 shs
Market Capitalization
$46.13 billion
P/E Ratio
41.12
Dividend Yield
N/A
Price Target
$756.00
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions. The company also operates commercial reference laboratories that provide routine and specialty testing, and offers software and connectivity platforms that deliver laboratory results, imaging and practice-management functionality to veterinary practices. In addition to companion animal diagnostics, IDEXX provides testing and monitoring solutions for dairy herd management, livestock health and water quality.

Founded in the early 1980s and based in Maine, IDEXX has grown into a multinational business with operations and customers across North America, Europe, the Asia-Pacific region and Latin America. Its customer base spans independent and corporate veterinary practices, academic and research institutions, municipal and industrial water utilities, and participants in the food supply chain. The company emphasizes recurring revenue streams from consumables and laboratory services alongside instrument sales, supported by ongoing research and development efforts to expand diagnostic capabilities and digital offerings.

IDEXX positions itself as a technology-driven diagnostics company focused on improving decision-making for animal and public health. Its strategy centers on broadening its diagnostic menu, strengthening laboratory and digital service offerings, and supporting veterinary and public health customers with integrated solutions that aim to improve clinical outcomes and operational efficiency.

AI Generated. May Contain Errors.

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 81% of companies evaluated by MarketBeat, and ranked 134th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 6 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    IDEXX Laboratories has a consensus price target of $756.00, representing about 29.3% upside from its current price of $584.78.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 3 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 12.14% in the coming year, from $14.74 to $16.53 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 41.12, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.50.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 41.12, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 280.35.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 3.21. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 28.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.68% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 2.99, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 8.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for IDEXX Laboratories this week, compared to 6 articles on an average week.
  • Search Interest

    Only 3 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.79% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Stock News Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories Q2 2026 Earnings Call Transcript
Aerial view of a water treatment plant with circular clarifiers, pipelines, and a reservoir behind it.
These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending (IDXX)
As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $676.53 at the beginning of 2026. Since then, IDXX shares have decreased by 13.6% and is now trading at $584.78.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Tuesday, August, 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The business's revenue for the quarter was up 9.7% compared to the same quarter last year.
Read the conference call transcript
.

IDEXX Laboratories' top institutional shareholders include Assenagon Asset Management S.A. (0.23%), Seilern Investment Management Ltd (0.12%), Manitou Investment Management Ltd. (0.09%) and Beacon Investment Advisory Services Inc. (0.07%). Insiders that own company stock include Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Michael Lane, Sharon E Underberg, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
8/04/2026
Today
8/05/2026
Investor Day 2026
8/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:IDXX
CIK
874716
Employees
11,000
Year Founded
1983

Price Target and Rating

High Price Target
$830.00
Low Price Target
$670.00
Potential Upside/Downside
+29.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$13.58
Trailing P/E Ratio
41.12
Forward P/E Ratio
39.67
P/E Growth
3.21
Net Income
$1.06 billion
Net Margins
25.03%
Pretax Margin
31.28%
Return on Equity
71.96%
Return on Assets
33.60%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
1.17
Quick Ratio
0.82

Sales & Book Value

Annual Sales
$4.30 billion
Price / Sales
10.72
Cash Flow
$15.00 per share
Price / Cash Flow
38.98
Book Value
$20.44 per share
Price / Book
28.61

Miscellaneous

Outstanding Shares
78,880,000
Free Float
78,260,000
Market Cap
$46.13 billion
Optionable
Optionable
Beta
1.54

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners